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Tox/Path Team
Takes On
Differential Gene
Expression
Toxicology and pathology are critical ele-
ments in toxicogenomics studies. The
National Center for Toxicogenomics
(NCT) has established a Tox/Path team
that includes both NCT scientists and tox-
icologists and pathologists from the
National Toxicology Program (NTP). The
Tox/Path team advises the NCT by for-
mulating research questions, designing
studies, and mining databases for informa-
tion. NTP members of the Tox/Path team
also bring their toxicogenomics expe-
rience to bear on study design and
assessment of proposed NTP toxi-
cogenomics evaluations.
One of the goals of the NCT is to
determine whether phenotypic alter-
ations can be associated with differen-
tial gene expression (DGE) changes. To
help meet this goal, the Tox/Path team
has designed a series of studies to elicit
different responses within the liver to
determine whether DGE can distin-
guish specific pathological processes.
Correlating Phenotypic
Alterations with DGE Changes
Initial Tox/Path liver studies focused
on acetaminophen, a compound that
causes centrilobular hepatic necrosis.
Acetaminophen has been widely stud-
ied both because of its importance as a
drug for humans (misuse of aceta-
minophen is the most common reason
for admission to emergency rooms
with acute liver toxicity) and because
it exerts a specific regional acute cen-
trilobular (zone 3) necrosis in the liver. 
Pathological evaluations awaiting publi-
cation have revealed that acetaminophen-
induced hepatic necrosis is not uniformly
distributed throughout the liver. Further
study has revealed differences in the extent
of lesions among the liver lobules. The
Tox/Path team has designed studies to eval-
uate the distribution of lesions throughout
the liver. These studies will use magnetic
resonance imaging to obtain a three-dimen-
sional view of the liver. This technology
may also allow the researchers to follow the
development of lesions using noninvasive
techniques, and possibly to correlate data
obtained by noninvasive techniques with
the development of lesions. 
In addition to the acetaminophen stud-
ies, a second compound under study is the
industrial chemical carbon tetrachloride, a
known liver carcinogen also known to cause
acute hepatic centrilobular necrosis.
Comparison of acetaminophen and carbon
tetrachloride may help to identify DGE
changes that are specific to centrilobular
hepatic necrosis and possibly differentiate
between pathways to toxicity. 
Allyl alcohol, also a large-scale industrial
chemical, causes a different form of liver
toxicity: acute hepatic periportal (zone 1)
necrosis. Allyl alcohol will be contrasted
with acetaminophen and carbon tetrachlo-
ride to further probe variable genetic path-
ways to toxicity. Other chemicals that target
specific subpopulations in the liver such as
biliary epithelial or endothelial cells are
under consideration for study.
One issue in associating phenotypic
alterations with DGE changes involves his-
tological sampling relative to sampling for
gene expression. In some cancer studies, a
frozen-tissue histological analysis is per-
formed on each sample before is it subjected
to RNA isolation for gene expression.
Although this provides a direct morphologi-
cal diagnosis for each DGE sample, such
sampling is too time-consuming and expen-
sive for most toxicogenomics studies. The
Tox/Path team is exploring means for taking
histological samples immediately adjacent to
the samples taken for DGE analysis to
ensure the least amount of variance in the
tissue samples used for different assays.
Julie Foley, a researcher in the Lab-
oratory of Experimental Pathology, is inves-
tigating yet another sampling technology:
laser-capture microscopy coupled with
RNA amplification for gene expression.
This method would allow regional sampling
of the liver, for example of centrilobular
hepatocytes versus periportal hepatocytes.
Comparing such samples is critical for
hepatic toxicants where the lesions appear
regionally. Laser-capture microscopy would
also allow NCT researchers to target specific
cell populations within the liver, taking
DGE from the tissue to the cellular level.
Controlling the Variables
There are many parameters that may affect
toxicogenomics study results, and the
experimental details are crucial to DGE
interpretation. For example, the composi-
tion of the test animal diet and circadian
rhythms can profoundly affect gene
expression. Due to their nocturnal
nature, rodents will naturally eat dur-
ing the night and sleep during the
day, resulting in diurnal differences
in liver glycogen and glutathione
content that affect metabolism and
toxicity of compounds. This circadi-
an cycle has profound effects on
DGE in the liver. 
NCT protocols have been
designed to control for time of dos-
ing, light/dark cycles, feeding sched-
ules, time of tissue collection, and
other factors that may influence
DGE. Where the palatability of the
feed may induce changes in the time
or amount of feed consumed,
appropriate controls are included.
The decision to fast animals
overnight prior to morning dosing
is questionable for DGE studies,
because fasting is a powerful stres-
sor. Room temperature, humidity,
number of animals per cage, and
even the person conducting the
experiment have all been suggested to con-
tribute to differences in transcription. The
Tox/Path team is still considering how to
control for these variables.
Chemical and toxicokinetic parameters
are also important to toxicogenomics stud-
ies. Toxicokinetic data help in the selection
of time points depending on peak chemical
or metabolite concentration in the target
tissue (time points are often selected when
the chemical can be expected to be cleared
from the tissue). Understanding when
pathological lesions may appear and the
development of the pathological response
to injury is also important in determining
the time intervals for sampling for DGE.
The route of exposure is critical
because it can influence serum and tissue
concentration levels, and also affects the
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Looking at livers. The Tox/Path group is using rat liver studies
to elucidate whether phenotypic alterations can be associated
with differential gene expression changes.kinetics of distribution and elimination of
the compound. Intravenous and intraperi-
toneal exposure results in faster and higher
plasma and tissue concentrations than oral
gavage, dietary, or drinking water expo-
sure. Unlike oral exposure, in which the
liver is exposed primarily through the first
pass portal venous blood, intravenous and
intraperitoneal routes expose the liver by
arterial perfusion. Enzymes within the
stomach, the intestine, and the cells of the
intestinal wall may modify many chemi-
cals. Selection of the route and duration of
exposure to match expected human expo-
sure is the choice for most studies. 
Variables in the animal model also may
influence toxicogenomics studies. Strain
differences between commercially available
rodents may, in some cases, reflect differ-
ences in metabolic rates. Murine viruses
and pathogenic bacteria confound experi-
ments, so there is an emphasis on specific
pathogen-free rodent sources and an active
sentinel animal program. 
Selection of the appropriate indicators
of toxicity is highly important. If the pur-
pose of the toxicogenomics study is to eval-
uate the gene changes during progression
of a toxic effect (such as necrosis or apo-
ptosis), then adequate documentation of
that altered phenotype is critical. For many
experiments, the standard battery of clini-
cal chemistry and histopathology assays is
sufficient to document the desired pheno-
typic changes. However, hematological
evaluations may be necessary if alterations
in blood cell number or composition are
suspected. Special histopathological or
immunohistochemistry stains may be
needed to document apoptosis, increased
cell proliferation, or other end points.
Subtle changes that occur at low doses may
require ultrastructure analysis. For subtle
changes, immersion fixation of tissue sam-
ples for ultrastructure analysis may not be
adequate, and a special study with fixation
by liver perfusion may be necessary to
avoid artifacts of fixation. 
When the goal of the study is to trans-
late the results to clinical practice, selection
of surrogate tissues should be considered.
Blood sampling for DGE, which offers the
advantage of multiple sampling over time
with minimal distress to the animal, is fea-
sible, although not fully validated.
Proteomic analysis of serum or plasma may
also be performed on these samples, and
may prove to be as useful as DGE analysis.
Extensive validation is still required at the
present time. However, the value of being
able to follow gene changes in an easily
acquired human sample makes the effort to
develop blood sampling worthwhile. 
Challenge and Promise
One challenge for correlating pathology
diagnoses with DGE analysis involves
standardizing pathology terminology.
Especially with acute toxicities, multiple
morphological diagnoses can be accurate
and convey essentially the same informa-
tion, and yet use different terms. To
address this communication problem, the
NCT is utilizing the NTP approach
whereby each study has a study patholo-
gist, a reviewing pathologist, and a
pathology panel (known as a pathology
working group) to ensure consistency and
uniformity of diagnoses within and across
studies. Tox/Path researcher Dave
Malarkey is also working with the
International Life Sciences Institute on an
effort to standardize pathology terminolo-
gy for toxicogenomics studies.
Another means of informing this
process may be to include a description of
the diagnostic process in the published
study results and in databases. For exam-
ple, with acute acetaminophen exposure,
the process is acute hepatic centrilobular
necrosis and repair; however, specific
morphological diagnoses vary with time
and dose.
Another challenge for toxicogenomics
studies lies in dealing with the rapidly
evolving technology, the extensive litera-
ture on each chemical, and the vast
amount of data generated by even a mod-
est experiment. But including multiple
disciplines in study design, study conduct,
data mining, and data interpretation is
proving useful to the NCT teams, and pro-
vides an added benefit of a camaraderie that
is helpful in combining resources to face a
daunting list of differentially expressed
genes. Both toxicologists and
pathologists have the background
and training to contribute to toxi-
cogenomics. The NCT Tox/Path
team allows both disciplines to
bring their strengths to bear on
the issues.
The task of the Tox/Path team
is exciting, if at times overwhelm-
ing. The potential advantage of
adding genomic technology to
toxicology evaluations is vast.
Shorter studies, fewer animals,
and less expense are among the
obvious advantages. Far greater
potential benefits include the
ability to recognize precursor
lesions or biomarkers of effect
that may be applicable to
humans exposed in the work-
place or the environment.
Furthermore, understanding the
pathways and mechanisms of
toxicity may lead to better thera-
peutic interventions and treat-
ment of diseases. –Michael L.
Cunningham, Richard Irwin, and
Gary Boorman
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It’s all in the details. Tox/Path researchers are designing toxicogenomics studies to control for a diverse array
of variables such as animal strain, circadian cycle, time of tissue sampling, animal housing, and others, all of
which may affect differential gene expression.